Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab and LB-100 in Ovarian Clear Cell Carcinoma
NCT06065462Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2023
- Primary completion
- Oct 2027
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dostarlimab, LB-100 in ovarian clear cell carcinoma (OCCC), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2023; status: recruiting.
02
Drugs
dostarlimabLB-100
03
Conditions
ovarian clear cell carcinoma (OCCC)
Beyond the preview
Go deeper on NCT06065462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06065462.